MAPT and early-onset autosomal dominant Alzheimer disease: Current criteria for the neuropathological diagnosisof AD by National Institutes of Aging-Alzheimer's Association87 uses 3 parameters including (A)immunohistochemistry-derived Aβ plaque score described by Thal etal.,88 (B) NFTs stage fromimmunohistochemistry for tau or phosphor-tau, and (C) neuritic plaque score fromThioflavin S or modified Bielschowsky as recommended by Consortium to Establish aRegistry for Alzheimer's disease (CERAD) protocol to obtain "ABC" score andtransform into one of four levels of AD neuropathologic change: Not, Low,Intermediate or High.